Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
HCC70	Everolimus	1	72	flat	flat	HCC70 everolimus 0 1 72	8	1.366	Inf	0.569	0.354	0.0	0.569	0.01	0.623	0.0534	0.643	Inf	0.718	0.766	0.0	0.718	0.01	0.62	0.0547	0.765
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
HCC38	Buparlisib	1	72	sigmoid	sigmoid	HCC38 buparlisib 0 1 72	8	1.738	0.912	-0.226	0.194	1.46	-0.57	1.62	0.999	9.48e-10	NA	1.2	0.192	0.858	1.12	0.0495	1.66	0.998	4.36e-09	NA
HCC70	AZD8055	3	72	sigmoid	sigmoid	HCC70 AZD8055 0 3 72	8	2.442	Inf	0.571	0.287	0.0133	0.574	1.17	0.98	8.55e-06	NA	Inf	0.554	0.694	0.0116	0.556	1.17	0.974	1.69e-05	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
HCC1806	AZD8055	3	72	sigmoid	sigmoid	HCC1806 AZD8055 0 3 72	8	3.185	Inf	0.593	0.215	0.0523	0.583	1.19	0.995	1.36e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC38	Sirolimus	2	72	flat	flat	HCC38 rapamycin 0 2 72	8	2.106	Inf	0.588	0.371	0.0	0.588	0.01	0.496	0.128	0.629	Inf	0.616	0.65	0.0	0.616	0.01	0.246	0.429	0.649
HCC38	Omipalisib	3	72	sigmoid	sigmoid	HCC38 omipalisib 0 3 72	8	1.446	0.0145	-0.503	0.802	0.0539	-0.597	0.6	0.993	3.08e-07	NA	0.0449	0.134	0.499	0.0308	0.107	0.644	0.993	2.98e-07	NA
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC70	Everolimus	3	72	sigmoid	sigmoid	HCC70 everolimus 0 3 72	8	2.401	530906.0	0.749	0.195	0.072	0.603	0.1	0.706	0.0255	NA	381983.0	0.725	0.782	0.0137	0.59	0.1	0.706	0.0255	NA
BT-549	CAL-101	1	72	sigmoid	sigmoid	BT549 idelalisib 0 1 72	8	1.791	Inf	0.836	0.041	4.8	0.605	0.778	0.924	0.00044	NA	Inf	0.858	0.964	4.79	0.659	0.767	0.92	0.000518	NA
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC70	CAL-101	2	72	sigmoid	sigmoid	HCC70 idelalisib 0 2 72	8	1.738	Inf	0.62	0.0432	0.959	0.611	3.13	0.965	4.31e-05	NA	Inf	0.693	0.965	0.935	0.686	3.13	0.96	6.52e-05	NA
Hs 578T	Torin2	3		sigmoid	sigmoid	Hs578T Torin2 3	8	2.844	0.0272	-0.327	0.667	0.144	-0.614	0.48	0.994	2.62e-07	NA	0.0164	0.0451	0.381	0.0148	0.0308	0.638	0.995	1.07e-07	NA
Hs 578T	Alpelisib	3		sigmoid	sigmoid	Hs578T alpelisib 3	8	2.856	Inf	0.712	0.0759	0.872	0.616	0.828	0.963	5.21e-05	NA	Inf	0.641	0.901	0.65	0.553	0.853	0.955	8.85e-05	NA
Hs 578T	KIN001-244	3		sigmoid	sigmoid	Hs578T KIN001-244 3	8	2.888	Inf	0.866	0.00909	5.05	0.617	1.35	0.858	0.00289	NA	50.0	0.818	0.988	5.2	0.474	1.31	0.842	0.00391	NA
Hs 578T	Sirolimus	2		flat	flat	Hs578T rapamycin 2	8	2.536	Inf	0.623	0.341	0.0	0.623	0.01	0.16	0.593	0.66	Inf	0.589	0.623	0.0	0.589	0.01	-0.232	1.0	0.624
HCC70	Buparlisib	3	72	sigmoid	sigmoid	HCC70 buparlisib 0 3 72	8	2.439	0.968	-0.156	0.167	1.7	-0.624	1.43	0.995	1.16e-07	NA	0.944	0.122	0.852	0.944	0.0	1.57	0.988	1.57e-06	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
HCC38	Torin2	2	72	sigmoid	sigmoid	HCC38 Torin2 0 2 72	8	2.140	0.0146	-0.48	0.793	0.0654	-0.634	0.545	0.993	3.78e-07	NA	0.0176	0.056	0.391	0.015	0.0502	0.68	0.989	1.33e-06	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)